Articles Archives
09/13/2025
Cryoport Systems Wins Best Cell & Gene Therapy Supplier Award at APCGTEA 2025
Cryoport Systems is proud to announce that we have been awarded Best Cell & Gene Therapy Supplier – Cell Processing Systems at the 2025 Asia-Pacific Cell & Gene Therapy Excellence Awards (APCGTEA).
09/10/2025
Scale Smarter: How Global Supply Chain Centers Amplify CGT Program Growth
Cell and gene therapy (CGT) programs are among the most complex and sensitive operations in the life sciences. From cryopreservation and biostorage to logistics and regulatory compliance, every step in the supply chain can influence product integrity, clinical timelines, and the scalability of the program. For program heads as well as clinical and technical operations teams, the challenge becomes bigger than merely moving materials. It quickly becomes a challenge of scaling efficiently while maintaining compliance and supporting growth across a global network.
07/22/2025
What’s Next for the CGT Industry? Mid-Year Check-In from the Leadership Team
We’re halfway through 2025, and the cell and gene therapy (CGT) landscape stands at a crossroads. Innovation continues to advance, yet the infrastructure required to support commercialization remains under pressure. To assess the current state of the industry and what’s ahead, Cryoport Systems gathered candid insights from our internal leaders across functions, from product development and commercial strategy to operations and client engagement.
06/24/2025
When Every Hour Counts: How Cryoport Systems Rapidly Mobilized to Protect INmune Bio’s Critical Clinical Materials
Biopharmaceutical development, particularly for advanced CGTs, relies on a robust infrastructure of logistics, BioServices, and temperature-controlled supply chains to ensure timely and intact delivery of drug products under stringent regulations. INmune Bio Inc. faced a challenge when a sudden biostorage site closure jeopardized a key clinical trial. However, with a strong support network, they turned to established partners like Cryoport Systems to overcome the crisis.
06/14/2025
Recognizing Donors and Advancing the Future of Cell Therapy
World Blood Donor Day serves as a reminder of the life-saving impact of voluntary blood and cell donations. These donations, often behind the scenes and not always recognized, are essential to emergency and surgical medicine and increasingly play an important role in cell and gene therapies. At Cryoport Systems, we recognize the incredible value of donors. We also understand that moving these donations safely, reliably, and under the strictest conditions, is a critical link between compassion and cure.
06/04/2025
Engineering for Impact: A Conversation with Mike Dybicz on the HV3 and Safepak Systems
When it comes to cell and gene therapy (CGT) logistics, innovation is about more than improving efficiency, it’s about safeguarding a patient’s only chance at treatment. We sat down with Mike Dybicz, Senior Vice President & Chief Product Development Officer, to discuss how Cryoport Systems is reshaping the future of CGT logistics with innovative products such as Cryoport Express® Cryogenic HV3 Shipping System and Safepak® System 1800, designed specifically to reduce risk, increase reliability, and ultimately improve patient outcomes.
05/19/2025
Addressing the EMEA Cold Chain Challenge for Cell and Gene Therapies: Cryoport Systems Featured in Labiotech.eu
In a recent Labiotech.eu article, Florent Belon, Managing Director for Cryoport Systems in France, discusses how regulatory diversity, infrastructure gaps, and extreme climate variation across EMEA intensify the need for customized, compliant cold chain solutions.
04/29/2025
Optimizing Cryopreservation for Leukapheresis: Advancing Cell and Gene Therapy Supply Chains
The supply chain for fresh leukapheresis is one of the most complex logistical challenges in cell and gene therapy (CGT). As a critical starting material, leukapheresis must be collected from donors, processed, and transported within a limited time window. These challenges increase variability and risk, ultimately impacting the success of advanced therapies. Alexandre Michaux, Process Development & MSAT Manager at IntegriCell™ , recently presented his work on the development of an automated cryopreservation process for leukapheresis in a Poster Presentation at Advanced Therapies Congress in London.
04/22/2025
